APPENDICES. A systematic review and economic model of the ...

246
Appendix 12
Core symptoms Educational performance Quality of life Adverse events
STESS (parents and physican)
Decreased appetite (n = 48), %,
mild/moderate/severe:
MPH: 40/35/10
DEX: 40/42/13
PLA: 0/0/0
MPH/DEX > PLA, p < 0.01
Not reported CGI Scale (physician)
Results presented in graphs
MPH > placebo, DEX > placebo,
p < 0.05
CTRS, Hyperactivity
Results presented in graphs
MPH > placebo, DEX > placebo, p < 0.05
C-GAS
Results presented in graphs
MPH > placebo, DEX > placebo,
p < 0.05
CPQ, Hyperactivity
Results presented in graphs
MPH > placebo, DEX > placebo, p < 0.05
Sleep difficulties (n = 48):
MPH: 40/31/8
DEX: 31/40/10
PLA: 23/4/0
MPH/DEX > PLA, p < 0.01
Overly meticulous (n = 33):
MPH: 30/3/0
DEX: 18/12/6
PLA: 0/0/0
MPH > PLA, p < 0.05; DEX > PLA,
p < 0.01
Not happy (n = 48):
MPH: 27/35/6
DEX: 25/33/4
PLA: 31/15/2
MPH > PLA, p < 0.01; DEX > PLA,
p < 0.05
Children’s Psychiatric Rating Scale: nervous
mannerisms (n = 34):
MPH: 26/21/3
DEX: 35/9/0
PLA: 15/0/0
MPH > PLA, p < 0. 01
Conclusions Authors’ conclusions: The authors concluded that both drugs were highly and equally efficacious for the group as a whole,
and frequently one drug or the other was superior for an individual child, or adverse effects occurred only on one of the
stimulants. They further note that non-response appears to be extremely rare when both stimulants and a wide range of
doses are given
Reviewer’s comments: No comments noted
PLA, placebo.